
Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs
Eli Lilly announced a $3.5 billion manufacturing plant in Pennsylvania’s Lehigh Valley to produce its next-generation obesity therapies, including the experimental drug retatrutide. The new facility, Lilly’s fourth major U.S. site, is slated to start this year and become operational in 2031, creating about 850 local jobs and 2,000 construction roles, as the company seeks to expand capacity amid strong GLP-1 market competition and ongoing push to secure drug supply.













